JAMA Medical News Cardiovascular Highlights From ESC 2025
11 snips
Sep 19, 2025 Felix Mahfoud, MD, is a renowned cardiologist and chair of the Department of Cardiology at University Hospital Basel. He discusses groundbreaking insights from the European Society of Cardiology Congress, particularly how GLP-1 therapies significantly lower hospitalizations for heart failure. He highlights mixed results regarding β-blockers after myocardial infarction and emphasizes the benefits of clopidogrel over aspirin for secondary prevention. Additionally, a meta-analysis reveals that shingles vaccination may reduce heart attack and stroke risk, showcasing the intersection of vaccines and cardiovascular health.
AI Snips
Chapters
Transcript
Episode notes
GLP-1 Therapies Lower HFpEF Events
- Semaglutide and tirzepatide reduced the composite of heart-failure hospitalization and all-cause death in patients with cardiometabolic HFpEF.
- The benefit appeared similar between the two agents despite larger weight loss with tirzepatide.
Beta-Blocker Benefit Varies With EF
- Two randomized trials of beta blockers after MI in patients with EF >40% produced conflicting results.
- Meta-analysis suggests benefit for patients with mildly reduced EF (41–49%), while benefit is unclear for EF ≥50%.
Prefer Clopidogrel For Long-Term CAD
- Prefer clopidogrel over aspirin for long-term single antiplatelet therapy in coronary artery disease based on pooled trial data.
- Clopidogrel reduced MACE by 14% at 5 years without increasing major bleeding or mortality.